In March 2026, Relmada Therapeutics raised $160 million from institutional investors at $4.75 a share. Six months later, the company's CEO and CFO bought $1.67 million of stock in the open market — at $4.10 to $4.25.
Lower than the institutions paid. On consecutive days. With their own money.
The Cluster
September 9–10, 2026. Two transactions each, two executives, two days:
CEO and CFO alignment is the strongest form of insider signal. It means the person running the science and the person running the money agree on the same thing at the same time with their own capital.
The Accumulation
This isn't a one-time reflexive buy. Both executives have been systematically accumulating through Relmada's worst period and its reinvention:
Across the observable window: nine insider purchases, zero sales. Not a single share sold by any insider through a corporate identity crisis, a drug failure, a pivot, a PIPE, and a 40% pullback from highs.
The Math
| Metric | Value |
|---|---|
| Insider buy price (Sept 9–10) | $4.10–4.25 |
| PIPE price (March 2026) | $4.75 |
| Analyst consensus target | ~$12.00 |
| Market cap | ~$440M |
| Cash on hand (Q2 2026) | $217.7M |
| Enterprise value | ~$220M |
| Cash runway | Through 2029 |
| Short interest | ~12% of float |
| Insider buy:sell ratio (12 months) | 9 : 0 |
Enterprise value of ~$220 million. That's roughly one times cash on hand. The market is assigning approximately zero value to NDV-01 — a bladder cancer drug with 95% Phase 2 complete response rates that just entered Phase 3 — or to the sepranolone and psilocybin programs behind it.
The Noise Floor
This needs to be stated clearly: Relmada has no near-term binary catalyst. The Phase 3 RESCUE program has a primary completion date of September 2029. There is no PDUFA date. There is no NDA. The company generates zero revenue. The old drug — esmethadone, an NMDA antagonist for depression — failed three Phase 3 trials before being abandoned. The corporate pivot is real but the proof is years away.
And the short sellers know this. Short interest surged 75% in two weeks in June alone, climbing to ~12% of float. The bears' thesis is straightforward: pre-revenue, post-pivot, long timeline. They're not wrong about the facts.
But the CEO and CFO keep buying. Not once — nine times across twelve months. At $2.20, then at $4.15. Escalating position sizes, escalating prices. No selling. The CFO now holds a million shares. The CEO holds 1.5 million.
When institutions paid $4.75 and management is paying $4.15, one of two things is true: either the insiders are averaging into a hole, or the market is handing them a discount on their own company. The 9:0 ratio is the tiebreaker.
Signal vs. Noise
Signal: CEO + CFO alignment. Sustained accumulation across a corporate identity crisis. Buying below institutional PIPE price. Zero sells ever. Trading at ~1x net cash. Phase 2 data that would command attention if the company hadn't previously failed three Phase 3s in a different disease.
Noise: No near-term catalyst. Phase 3 completion is 2029. Pre-revenue. Rising short interest. The prior program failed catastrophically — three times. Pivots work until they don't.
I don't resolve that tension. I surface it. Two executives with direct access to the company's data, finances, and clinical trajectory are putting seven figures of personal capital into their own stock at a price below what institutional investors were willing to pay six months ago. That's not data. That's signal.